A case of choroidal neovascularization as a first manifestaion of systemic lupus erythematosus.
Anti-cardiolipine
Choroidal neovascularization
Fluorescein angiography
Intra-vitral injection of anti-VEGF
OCT
Systemic lupus erythematosus
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
04
02
2024
accepted:
25
03
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
To report a rare occurrence of pigment epitheliopathy associated with choroidal neovasculization as a first manifestation of systemic lupus erythematosus. A 54-year-old female, with no prior medical history, sought a second opinion due to sudden drop in vision in her right eye to 20/80. Slit lamp examination was normal. Fundus examination revealed the presence of a subretinal hemorrhage in the macular area. Fundus imaging including optical coherence tomography and fluorescein angiography showed multifocal retinal pigment epitheliopathy associated with choroidal neovascularization (CNV). The patient had received an intravitreal injection of Bevacizumab 2 weeks ago. It was decided to complete the loading dose regimen with two additional Bevacizumab injections, and the first injection was done 2 weeks after her presentation. Two weeks later, the patient reported a rash on her cheeks, painful joints, and purpura. Systemic workup revealed positive ANA, anti-cardiolipin antibodies, and decreased complement levels, with negative anti-histone antibodies. This led to the diagnosis of systemic lupus erythematosus (SLE) based on the "Systemic Lupus International Collaborating Clinics" criteria. The patient was treated with 50 mg of prednisolone which was then tapered. 1 month after the third injection, an showed a total resolution of the sub-retinal fluid with an improvement of vision to 20/20. No recurrence was observed during follow-up. Based on the findings from the fundus exam and imaging, systemic symptoms and the blood work-up, we postulate that the pigment epitheliopathy associated with choroidal neovascularization was related to the vaso-occlusive disease at the level of the choroid that can be part of SLE vasculopathy. To our knowledge, this represents the first case in which pigment epitheliopathy and CNV were the primary manifestations of SLE.
Sections du résumé
BACKGROUND
BACKGROUND
To report a rare occurrence of pigment epitheliopathy associated with choroidal neovasculization as a first manifestation of systemic lupus erythematosus.
CASE PRESENTATION
METHODS
A 54-year-old female, with no prior medical history, sought a second opinion due to sudden drop in vision in her right eye to 20/80. Slit lamp examination was normal. Fundus examination revealed the presence of a subretinal hemorrhage in the macular area. Fundus imaging including optical coherence tomography and fluorescein angiography showed multifocal retinal pigment epitheliopathy associated with choroidal neovascularization (CNV). The patient had received an intravitreal injection of Bevacizumab 2 weeks ago. It was decided to complete the loading dose regimen with two additional Bevacizumab injections, and the first injection was done 2 weeks after her presentation. Two weeks later, the patient reported a rash on her cheeks, painful joints, and purpura. Systemic workup revealed positive ANA, anti-cardiolipin antibodies, and decreased complement levels, with negative anti-histone antibodies. This led to the diagnosis of systemic lupus erythematosus (SLE) based on the "Systemic Lupus International Collaborating Clinics" criteria. The patient was treated with 50 mg of prednisolone which was then tapered. 1 month after the third injection, an showed a total resolution of the sub-retinal fluid with an improvement of vision to 20/20. No recurrence was observed during follow-up.
CONCLUSION
CONCLUSIONS
Based on the findings from the fundus exam and imaging, systemic symptoms and the blood work-up, we postulate that the pigment epitheliopathy associated with choroidal neovascularization was related to the vaso-occlusive disease at the level of the choroid that can be part of SLE vasculopathy. To our knowledge, this represents the first case in which pigment epitheliopathy and CNV were the primary manifestations of SLE.
Identifiants
pubmed: 38698249
doi: 10.1007/s10792-024-03120-x
pii: 10.1007/s10792-024-03120-x
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Fava A, Petri M (2019) Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 96:1–13. https://doi.org/10.1016/J.JAUT.2018.11.001
doi: 10.1016/J.JAUT.2018.11.001
pubmed: 30448290
Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E (2022) Understanding ocular findings and manifestations of systemic lupus erythematosus: update review of the literature. Int J Mol Sci 23(20):12264. https://doi.org/10.3390/ijms232012264
doi: 10.3390/ijms232012264
pubmed: 36293119
pmcid: 9603180
Cunningham J, Alfred PR, Irvine AR (1996) Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology 103(12):2081–2090. https://doi.org/10.1016/S0161-6420(96)30385-0
doi: 10.1016/S0161-6420(96)30385-0
pubmed: 9003342
Grossniklaus HE, Green WR (2004) Choroidal neovascularization. Am J Ophthalmol 137(3):496–503. https://doi.org/10.1016/J.AJO.2003.09.042
doi: 10.1016/J.AJO.2003.09.042
pubmed: 15013874
Invernizzi A et al (2019) Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the fight retinal blindness! project. Am J Ophthalmol 204:105–112. https://doi.org/10.1016/J.AJO.2019.03.001
doi: 10.1016/J.AJO.2019.03.001
pubmed: 30862501
Journal O, Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, Mrejen S, Freund B (2014) Pachychoroid diseases of the macula. Med Hypothesis, Discov Innov Ophthalmol 3(4):111
de Azevedo LGB et al (2021) Lupus retinopathy: epidemiology and risk factors. Arq Bras Oftalmol 84(4):395–401. https://doi.org/10.5935/0004-2749.20210076
doi: 10.5935/0004-2749.20210076
pubmed: 34287516
Seth G et al (2018) Lupus retinopathy: a marker of active systemic lupus erythematosus. Rheumatol Int 38(8):1495–1501. https://doi.org/10.1007/S00296-018-4083-4
doi: 10.1007/S00296-018-4083-4
pubmed: 29948002
Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M (1988) Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 31(9):1105–1110. https://doi.org/10.1002/ART.1780310904
doi: 10.1002/ART.1780310904
pubmed: 3422014
Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK (2016) Systemic lupus erythematosus: an update for ophthalmologists. Surv Ophthalmol 61(1):65–82. https://doi.org/10.1016/J.SURVOPHTHAL.2015.06.003
doi: 10.1016/J.SURVOPHTHAL.2015.06.003
pubmed: 26197421
Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB (1986) Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol 104(4):558–563. https://doi.org/10.1001/ARCHOPHT.1986.01050160114025
doi: 10.1001/ARCHOPHT.1986.01050160114025
pubmed: 3954661
Ushiyama O et al (2000) Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis 59(9):705–708. https://doi.org/10.1136/ARD.59.9.705
doi: 10.1136/ARD.59.9.705
pubmed: 10976084
pmcid: 1753270
Vihinen P, Paija O, Kivisaari A, Koulu L, Aho H (2011) Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. J Med Case Rep 5:243. https://doi.org/10.1186/1752-1947-5-243
doi: 10.1186/1752-1947-5-243
pubmed: 21707979
pmcid: 3143101
cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature—jddonline—journal of drugs in dermatology. https://jddonline.com/articles/cutaneous-lupus-erythematosus-in-a-patient-undergoing-intravitreal-bevacizumab-injections-case-repor-S1545961613P1052X . Accessed 26 Mar 2023
FIRST AID FOR THE USMLE STEP 2 CK, 10th edn. McGraw Hill
Chan S, Gottlieb CC (2015) Systemic lupus erythematosus presenting as acute posterior multifocal placoid pigment epitheliopathy case report and review of the ocular manifestations of systemic lupus erythematosus. Int J Ophthalmol Clin Res 2:4–12
doi: 10.23937/2378-346X/1410038
Sawa M, Saito Y, Kameda C, Tano Y (2002) Ocular complications in systemic lupus erythematosus–choroidal and retinal pigment epithelial changes. Nihon Ganka Gakkai Zasshi 106(8):474–480. https://doi.org/10.1016/s0021-5155(02)00657-3
doi: 10.1016/s0021-5155(02)00657-3
pubmed: 12229197
Savastano MC, Rispoli M, Lumbroso B (2021) The incidence of neovascularization in central serous chorioretinopathy by optical coherence tomography angiography. Retina 41(2):302–308. https://doi.org/10.1097/IAE.0000000000002810
doi: 10.1097/IAE.0000000000002810
pubmed: 32310626
Raja L et al (2020) Choroidal neovascularization mimics in chronic central serous chorioretinopathy; an optical coherence tomography angiography study. Invest Ophthalmol Vis Sci 61(7):4811–4811
Kim RY, Ma GJ, Park WK, Kim M, Park YG, Park YH (2021) Clinical course after the onset of choroidal neovascularization in eyes with central serous chorioretinopathy. Medicine (Baltimore) 100(34):E26980. https://doi.org/10.1097/MD.0000000000026980
doi: 10.1097/MD.0000000000026980
pubmed: 34449466